AstraZeneca, which is working with the University of Oxford, hasn't said what the illness is. It will try to determine whether the illness is related to the vaccine, or just a chance event.
Several COVID-19 vaccine candidates are being tested now. But why does it take 30,000 volunteers to know if one is safe and effective? And what does it mean to say a vaccine candidate is working?
Associate Director of the Emory Vaccine Center Dr. Walter Orenstein says it's more likely to have a safe and effective COVID-19 vaccine early next year than this fall.
A Trump administration spokesman says Washington will continue to engage the rest of the world in vaccine development but won't be "constrained" by the "corrupt" World Health Organization.
A vaccine against the coronavirus needs to keep people from getting very sick and dying. But preventing the spread of the disease is also important, and vaccines delivered by nasal spray may do that.
It's the first country to approve a COVID-19 vaccine, but it has not finished Phase III trials to assess safety and effectiveness in the general population.
Moderna, one of the leading horses in the coronavirus vaccine race, has already made deals at between $32 and $37 a dose for some foreign countries. The U.S. price is expected to be lower.
Vaccine candidates are in advanced clinical trials, and WHO's director-general expresses hope they will be effective. But until then, he said, the world is reliant on "the basics" of disease control.
Studies involving COVID-19 vaccine candidates in monkeys show promise of an effective vaccine, but it will take large-scale human trials to know for sure if they work.
Recent studies have raised fears that immunity to the coronavirus might be fleeting, thus making potential vaccines ineffective. The reality of the science is more complex — and more reassuring.
When Norman Hulme heard Emory was opening its vaccine trial to people age 56 and over, he jumped at the chance. The 65-year-old grew up in New York, in...
